Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients
Previous studies have reported that selective serotonin reuptake inhibitors (SSRIs) may induce or exacerbate rapid eye movement (REM) sleep without atonia (RSWA) and increase the risk of developing REM sleep behavior disorder (RBD). However, most of these studies are retrospective and cross-sectiona...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2013-12, Vol.47, p.85-92 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | |
| container_start_page | 85 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 47 |
| creator | Zhang, Bin Hao, Yanli Jia, Fujun Tang, Yi Li, Xueli Liu, Wuhan Arnulf, Isabelle |
| description | Previous studies have reported that selective serotonin reuptake inhibitors (SSRIs) may induce or exacerbate rapid eye movement (REM) sleep without atonia (RSWA) and increase the risk of developing REM sleep behavior disorder (RBD). However, most of these studies are retrospective and cross-sectional and employed small sample sizes and a mixture of SSRIs. In this 8-week open-label trial of sertraline in depressed patients (n=31), depressed patients were administered 50mg sertraline at 8am on the 1st day and subsequently titrated up to a maximum of 200mg/day. All patients underwent repeated video-polysomnography (vPSG) (baseline, 1st day, 14th day, 28th day, and 56th day). Both tonic (submental) and phasic (submental and anterior tibialis) RSWA events were visually counted. Tonic RSWA increased from 3.2±1.8% at baseline to 5.1±2.3% on the 1st day and 10.4±2.7% on the 14th day; after that, measurements were stable until the 56th day. A similar profile was observed for phasic RSWA. The increases in tonic RSWA (r=0.56, P=0.004) and phasic RSWA (submental: r=−0.51, P=0.02; anterior tibialis: r=0.41, P=0.04) were correlated with the degree of the prolonging of REM latency. All of RSWAs were not correlated with patients' demographic and clinical characteristics. Sertraline may induce or exacerbate RSWA. In contrast to idiopathic RBD, sertraline-related RSWA had the specific characteristics of being correlated with the degree of the prolonging of REM latency and no predominance of male sex and elder age, suggesting different pathophysiological mechanisms. The antidepressant-related RSWA should be a potential public health problem in the depressed patients.
•Sertraline exacerbated Rapid eye movement (REM) sleep without atonia (RSWA).•Sertraline-related RSWA have no predominance of male sex and elder age.•Sertraline-related RSWA might have different mechanisms with idiopathic RBD.•RSWA might be potential public health problem in the depressed patients. |
| doi_str_mv | 10.1016/j.pnpbp.2013.08.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500778272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S027858461300184X</els_id><sourcerecordid>1500778272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-da4b3e80641572c5693d243991b0185235dba270469e29b5b8363842754972ac3</originalsourceid><addsrcrecordid>eNqF0UtrFTEUB_AgFntb_QSCZCO46Ix5T0ZwUYqPQsGFug6Z5FzMdR4xybTcb2_qvequXSWL33lw_gi9pKSlhKq3uzbOcYgtI5S3RLeEkidoQ3WnG8Goeoo2hNW_1EKdorOcd4RUSfgzdMp43wulyAaFr5BKsmOYAdvZ42Rj8Bj2gKflFiaYC84jQMR3ofxY1oJtWeZg3-HLGevmDuDnBV4izM1oBxhxLqvf42WLPcQEOYPH0ZZQ2-Tn6GRrxwwvju85-v7xw7erz83Nl0_XV5c3jROMlcZbMXDQRAkqO-ak6rlnou5LB0K1ZFz6wbKOCNUD6wc5aK64FqyTou-YdfwcvTn0jWn5tUIuZgrZwTjaGZY1GyoJ6TrNOvY4FVLXmbJXlfIDdWnJOcHWxBQmm_aGEnMfh9mZP3GY-zgM0abGUateHQeswwT-X83f-1fw-ghsdnbcJju7kP-7rpdV0ureHxzUy90GSCa7elUHPiRwxfglPLjIb0MYp7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458185596</pqid></control><display><type>article</type><title>Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zhang, Bin ; Hao, Yanli ; Jia, Fujun ; Tang, Yi ; Li, Xueli ; Liu, Wuhan ; Arnulf, Isabelle</creator><creatorcontrib>Zhang, Bin ; Hao, Yanli ; Jia, Fujun ; Tang, Yi ; Li, Xueli ; Liu, Wuhan ; Arnulf, Isabelle</creatorcontrib><description>Previous studies have reported that selective serotonin reuptake inhibitors (SSRIs) may induce or exacerbate rapid eye movement (REM) sleep without atonia (RSWA) and increase the risk of developing REM sleep behavior disorder (RBD). However, most of these studies are retrospective and cross-sectional and employed small sample sizes and a mixture of SSRIs. In this 8-week open-label trial of sertraline in depressed patients (n=31), depressed patients were administered 50mg sertraline at 8am on the 1st day and subsequently titrated up to a maximum of 200mg/day. All patients underwent repeated video-polysomnography (vPSG) (baseline, 1st day, 14th day, 28th day, and 56th day). Both tonic (submental) and phasic (submental and anterior tibialis) RSWA events were visually counted. Tonic RSWA increased from 3.2±1.8% at baseline to 5.1±2.3% on the 1st day and 10.4±2.7% on the 14th day; after that, measurements were stable until the 56th day. A similar profile was observed for phasic RSWA. The increases in tonic RSWA (r=0.56, P=0.004) and phasic RSWA (submental: r=−0.51, P=0.02; anterior tibialis: r=0.41, P=0.04) were correlated with the degree of the prolonging of REM latency. All of RSWAs were not correlated with patients' demographic and clinical characteristics. Sertraline may induce or exacerbate RSWA. In contrast to idiopathic RBD, sertraline-related RSWA had the specific characteristics of being correlated with the degree of the prolonging of REM latency and no predominance of male sex and elder age, suggesting different pathophysiological mechanisms. The antidepressant-related RSWA should be a potential public health problem in the depressed patients.
•Sertraline exacerbated Rapid eye movement (REM) sleep without atonia (RSWA).•Sertraline-related RSWA have no predominance of male sex and elder age.•Sertraline-related RSWA might have different mechanisms with idiopathic RBD.•RSWA might be potential public health problem in the depressed patients.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2013.08.010</identifier><identifier>PMID: 23994660</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Age ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Cross-Sectional Studies ; Depressed patient ; Depression ; Depression - complications ; Depression - drug therapy ; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Mood disorders ; Nervous system (semeiology, syndromes) ; Neurology ; Neuropharmacology ; Pharmacology. Drug treatments ; Polysomnography ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Rapid eye movement (REM) sleep without atonia (RSWA) ; REM sleep behavior disorder (RBD) ; REM Sleep Behavior Disorder - drug therapy ; REM Sleep Behavior Disorder - etiology ; Retrospective Studies ; Sertraline ; Sertraline - therapeutic use ; Time Factors ; Young Adult</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2013-12, Vol.47, p.85-92</ispartof><rights>2013 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>2013.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-da4b3e80641572c5693d243991b0185235dba270469e29b5b8363842754972ac3</citedby><cites>FETCH-LOGICAL-c422t-da4b3e80641572c5693d243991b0185235dba270469e29b5b8363842754972ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S027858461300184X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27959941$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23994660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Hao, Yanli</creatorcontrib><creatorcontrib>Jia, Fujun</creatorcontrib><creatorcontrib>Tang, Yi</creatorcontrib><creatorcontrib>Li, Xueli</creatorcontrib><creatorcontrib>Liu, Wuhan</creatorcontrib><creatorcontrib>Arnulf, Isabelle</creatorcontrib><title>Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Previous studies have reported that selective serotonin reuptake inhibitors (SSRIs) may induce or exacerbate rapid eye movement (REM) sleep without atonia (RSWA) and increase the risk of developing REM sleep behavior disorder (RBD). However, most of these studies are retrospective and cross-sectional and employed small sample sizes and a mixture of SSRIs. In this 8-week open-label trial of sertraline in depressed patients (n=31), depressed patients were administered 50mg sertraline at 8am on the 1st day and subsequently titrated up to a maximum of 200mg/day. All patients underwent repeated video-polysomnography (vPSG) (baseline, 1st day, 14th day, 28th day, and 56th day). Both tonic (submental) and phasic (submental and anterior tibialis) RSWA events were visually counted. Tonic RSWA increased from 3.2±1.8% at baseline to 5.1±2.3% on the 1st day and 10.4±2.7% on the 14th day; after that, measurements were stable until the 56th day. A similar profile was observed for phasic RSWA. The increases in tonic RSWA (r=0.56, P=0.004) and phasic RSWA (submental: r=−0.51, P=0.02; anterior tibialis: r=0.41, P=0.04) were correlated with the degree of the prolonging of REM latency. All of RSWAs were not correlated with patients' demographic and clinical characteristics. Sertraline may induce or exacerbate RSWA. In contrast to idiopathic RBD, sertraline-related RSWA had the specific characteristics of being correlated with the degree of the prolonging of REM latency and no predominance of male sex and elder age, suggesting different pathophysiological mechanisms. The antidepressant-related RSWA should be a potential public health problem in the depressed patients.
•Sertraline exacerbated Rapid eye movement (REM) sleep without atonia (RSWA).•Sertraline-related RSWA have no predominance of male sex and elder age.•Sertraline-related RSWA might have different mechanisms with idiopathic RBD.•RSWA might be potential public health problem in the depressed patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Age</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cross-Sectional Studies</subject><subject>Depressed patient</subject><subject>Depression</subject><subject>Depression - complications</subject><subject>Depression - drug therapy</subject><subject>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Polysomnography</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rapid eye movement (REM) sleep without atonia (RSWA)</subject><subject>REM sleep behavior disorder (RBD)</subject><subject>REM Sleep Behavior Disorder - drug therapy</subject><subject>REM Sleep Behavior Disorder - etiology</subject><subject>Retrospective Studies</subject><subject>Sertraline</subject><subject>Sertraline - therapeutic use</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0UtrFTEUB_AgFntb_QSCZCO46Ix5T0ZwUYqPQsGFug6Z5FzMdR4xybTcb2_qvequXSWL33lw_gi9pKSlhKq3uzbOcYgtI5S3RLeEkidoQ3WnG8Goeoo2hNW_1EKdorOcd4RUSfgzdMp43wulyAaFr5BKsmOYAdvZ42Rj8Bj2gKflFiaYC84jQMR3ofxY1oJtWeZg3-HLGevmDuDnBV4izM1oBxhxLqvf42WLPcQEOYPH0ZZQ2-Tn6GRrxwwvju85-v7xw7erz83Nl0_XV5c3jROMlcZbMXDQRAkqO-ak6rlnou5LB0K1ZFz6wbKOCNUD6wc5aK64FqyTou-YdfwcvTn0jWn5tUIuZgrZwTjaGZY1GyoJ6TrNOvY4FVLXmbJXlfIDdWnJOcHWxBQmm_aGEnMfh9mZP3GY-zgM0abGUateHQeswwT-X83f-1fw-ghsdnbcJju7kP-7rpdV0ureHxzUy90GSCa7elUHPiRwxfglPLjIb0MYp7c</recordid><startdate>20131202</startdate><enddate>20131202</enddate><creator>Zhang, Bin</creator><creator>Hao, Yanli</creator><creator>Jia, Fujun</creator><creator>Tang, Yi</creator><creator>Li, Xueli</creator><creator>Liu, Wuhan</creator><creator>Arnulf, Isabelle</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20131202</creationdate><title>Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients</title><author>Zhang, Bin ; Hao, Yanli ; Jia, Fujun ; Tang, Yi ; Li, Xueli ; Liu, Wuhan ; Arnulf, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-da4b3e80641572c5693d243991b0185235dba270469e29b5b8363842754972ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Age</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cross-Sectional Studies</topic><topic>Depressed patient</topic><topic>Depression</topic><topic>Depression - complications</topic><topic>Depression - drug therapy</topic><topic>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Polysomnography</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rapid eye movement (REM) sleep without atonia (RSWA)</topic><topic>REM sleep behavior disorder (RBD)</topic><topic>REM Sleep Behavior Disorder - drug therapy</topic><topic>REM Sleep Behavior Disorder - etiology</topic><topic>Retrospective Studies</topic><topic>Sertraline</topic><topic>Sertraline - therapeutic use</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Hao, Yanli</creatorcontrib><creatorcontrib>Jia, Fujun</creatorcontrib><creatorcontrib>Tang, Yi</creatorcontrib><creatorcontrib>Li, Xueli</creatorcontrib><creatorcontrib>Liu, Wuhan</creatorcontrib><creatorcontrib>Arnulf, Isabelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Bin</au><au>Hao, Yanli</au><au>Jia, Fujun</au><au>Tang, Yi</au><au>Li, Xueli</au><au>Liu, Wuhan</au><au>Arnulf, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2013-12-02</date><risdate>2013</risdate><volume>47</volume><spage>85</spage><epage>92</epage><pages>85-92</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Previous studies have reported that selective serotonin reuptake inhibitors (SSRIs) may induce or exacerbate rapid eye movement (REM) sleep without atonia (RSWA) and increase the risk of developing REM sleep behavior disorder (RBD). However, most of these studies are retrospective and cross-sectional and employed small sample sizes and a mixture of SSRIs. In this 8-week open-label trial of sertraline in depressed patients (n=31), depressed patients were administered 50mg sertraline at 8am on the 1st day and subsequently titrated up to a maximum of 200mg/day. All patients underwent repeated video-polysomnography (vPSG) (baseline, 1st day, 14th day, 28th day, and 56th day). Both tonic (submental) and phasic (submental and anterior tibialis) RSWA events were visually counted. Tonic RSWA increased from 3.2±1.8% at baseline to 5.1±2.3% on the 1st day and 10.4±2.7% on the 14th day; after that, measurements were stable until the 56th day. A similar profile was observed for phasic RSWA. The increases in tonic RSWA (r=0.56, P=0.004) and phasic RSWA (submental: r=−0.51, P=0.02; anterior tibialis: r=0.41, P=0.04) were correlated with the degree of the prolonging of REM latency. All of RSWAs were not correlated with patients' demographic and clinical characteristics. Sertraline may induce or exacerbate RSWA. In contrast to idiopathic RBD, sertraline-related RSWA had the specific characteristics of being correlated with the degree of the prolonging of REM latency and no predominance of male sex and elder age, suggesting different pathophysiological mechanisms. The antidepressant-related RSWA should be a potential public health problem in the depressed patients.
•Sertraline exacerbated Rapid eye movement (REM) sleep without atonia (RSWA).•Sertraline-related RSWA have no predominance of male sex and elder age.•Sertraline-related RSWA might have different mechanisms with idiopathic RBD.•RSWA might be potential public health problem in the depressed patients.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23994660</pmid><doi>10.1016/j.pnpbp.2013.08.010</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2013-12, Vol.47, p.85-92 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1500778272 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Adult and adolescent clinical studies Age Antidepressive Agents - therapeutic use Biological and medical sciences Cross-Sectional Studies Depressed patient Depression Depression - complications Depression - drug therapy Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes Female Follow-Up Studies Humans Male Medical sciences Middle Aged Mood disorders Nervous system (semeiology, syndromes) Neurology Neuropharmacology Pharmacology. Drug treatments Polysomnography Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Rapid eye movement (REM) sleep without atonia (RSWA) REM sleep behavior disorder (RBD) REM Sleep Behavior Disorder - drug therapy REM Sleep Behavior Disorder - etiology Retrospective Studies Sertraline Sertraline - therapeutic use Time Factors Young Adult |
| title | Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T21%3A15%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sertraline%20and%20rapid%20eye%20movement%20sleep%20without%20atonia:%20An%208-week,%20open-label%20study%20of%20depressed%20patients&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Zhang,%20Bin&rft.date=2013-12-02&rft.volume=47&rft.spage=85&rft.epage=92&rft.pages=85-92&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2013.08.010&rft_dat=%3Cproquest_cross%3E1500778272%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458185596&rft_id=info:pmid/23994660&rft_els_id=S027858461300184X&rfr_iscdi=true |